Mood Disorders Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

Mood Disorders Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

The 7 major mood disorders markets reached a value of US$ 3.7 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 4.5 Billion by 2034, exhibiting a growth rate (CAGR) of 1.78% during 2024-2034.

The mood disorders market has been comprehensively analyzed in IMARC's new report titled "Mood Disorders Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Mood disorders refer to a group of mental health conditions characterized by significant and persistent disturbances in a person's mood or emotional state. These illnesses can have a profound impact on the patient's daily functioning, relationships, and overall quality of life. The common indications of mood disorders include a persistent feeling of sadness, hopelessness, emptiness, or worthlessness, fatigue, decreased energy, loss of interest or pleasure, changes in appetite or weight, sleep disturbances, difficulty concentrating, agitation, suicidal ideation, chronic irritability, etc. Individuals suffering from these disorders may also experience manic symptoms, such as periods of elevated mood, increased energy, racing thoughts, impulsive behavior, etc. The diagnosis of these ailments involves a combination of methods to determine the patient's clinical features, along with personal and family history. Mental health professionals commonly refer to the Diagnostic and Statistical Manual of Mental Disorders (DSM-5), which provides specific criteria for diagnosing different mood disorders. Various standardized questionnaires, such as the Beck Depression Inventory (BDI) or the Hamilton Rating Scale for Depression (HAM-D), are also used to assess the severity and frequency of symptoms.

The increasing cases of abnormalities in the structure or functioning of the brain regions involved in regulating emotions, including the amygdala or prefrontal cortex, are primarily driving the mood disorders market. In addition to this, the rising prevalence of imbalances in neurotransmitters, like serotonin, dopamine, norepinephrine, etc., that can disrupt communication between neurons is also creating a positive outlook for the market. Moreover, the widespread adoption of dialectical behavior therapy to develop healthier coping mechanisms and reduce emotional vulnerability is further bolstering the market growth. Apart from this, the inflating application of typical antipsychotics, such as aripiprazole, quetiapine, olanzapine, etc., which work by blocking dopamine receptors in various regions of the brain to stabilize mood and alleviate agitation or aggression, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of non-invasive transcranial magnetic stimulation techniques, since they allow for more precise and localized activation of specific brain areas, thereby modulating neuronal activity and potentially restoring normal functioning, is expected to drive the mood disorders market during the forecast period.

IMARC Group's new report provides an exhaustive analysis of the mood disorders market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for mood disorders and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the mood disorders market in any manner.

Time Period of the Study

Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034

Countries Covered

United States
Germany
France
United Kingdom
Italy
Spain
Japan

Analysis Covered Across Each Country

Historical, current, and future epidemiology scenario
Historical, current, and future performance of the mood disorders market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the mood disorders market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current mood disorders marketed drugs and late-stage pipeline drugs.

In-Market Drugs

Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:
Market Insights

How has the mood disorders market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the mood disorders market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the mood disorders market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?

Epidemiology Insights

What is the number of prevalent cases (2018-2034) of mood disorders across the seven major markets?
What is the number of prevalent cases (2018-2034) of mood disorders by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of mood disorders by gender across the seven major markets?
What is the number of prevalent cases (2018-2034) of mood disorders by type across the seven major markets?
How many patients are diagnosed (2018-2034) with mood disorders across the seven major markets?
What is the size of the mood disorders patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of mood disorders?
What will be the growth rate of patients across the seven major markets?

Mood Disorders: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for mood disorders drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the mood disorders market?
What are the key regulatory events related to the mood disorders market?
What is the structure of clinical trial landscape by status related to the mood disorders market?
What is the structure of clinical trial landscape by phase related to the mood disorders market?
What is the structure of clinical trial landscape by route of administration related to the mood disorders market?